9,750 Shares in DexCom, Inc. (NASDAQ:DXCM) Purchased by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC acquired a new stake in DexCom, Inc. (NASDAQ:DXCM) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 9,750 shares of the medical device company’s stock, valued at approximately $654,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in DXCM. Vanguard Group Inc. increased its holdings in shares of DexCom by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company’s stock valued at $6,186,539,000 after purchasing an additional 136,282 shares in the last quarter. Legal & General Group Plc increased its holdings in DexCom by 1.7% in the second quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock valued at $339,352,000 after buying an additional 49,076 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of DexCom by 16.9% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock valued at $276,538,000 after acquiring an additional 353,019 shares during the period. 1832 Asset Management L.P. boosted its stake in shares of DexCom by 1.1% during the 1st quarter. 1832 Asset Management L.P. now owns 1,823,400 shares of the medical device company’s stock worth $252,906,000 after acquiring an additional 20,400 shares in the last quarter. Finally, Vaughan Nelson Investment Management L.P. grew its holdings in shares of DexCom by 14.4% in the 2nd quarter. Vaughan Nelson Investment Management L.P. now owns 1,617,001 shares of the medical device company’s stock worth $183,336,000 after acquiring an additional 203,043 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Activity

In related news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. The trade was a 0.28 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Sadie Stern sold 426 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This represents a 0.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.30% of the company’s stock.

DexCom Stock Performance

Shares of DXCM stock opened at $75.88 on Friday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The firm has a market capitalization of $29.64 billion, a price-to-earnings ratio of 45.44, a price-to-earnings-growth ratio of 2.22 and a beta of 1.17. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a 50 day moving average price of $69.89 and a 200 day moving average price of $92.01.

Analyst Upgrades and Downgrades

A number of analysts have commented on DXCM shares. Oppenheimer decreased their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Piper Sandler reiterated an “overweight” rating and issued a $90.00 price objective on shares of DexCom in a research report on Monday, August 26th. Royal Bank of Canada dropped their target price on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, October 25th. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $145.00 price target on shares of DexCom in a research report on Tuesday, July 23rd. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, DexCom has a consensus rating of “Moderate Buy” and an average target price of $104.59.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.